Navigation Links
GeoVax Labs, Inc. Announces Resignation of Director
Date:7/6/2009

collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.

GeoVax's AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $17 million IPCAVD grant awarded in late 2007.

Safe Harbor Statement

All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-l
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois
2. GeoVax to Exhibit at the 2009 BIO International Convention
3. GeoVax Labs, Inc. Announces First Quarter Financial Results
4. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
5. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
6. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
7. GeoVax to Present at the BIO CEO & Investor Conference 2009
8. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
9. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
10. GeoVax Presents Data at AIDS Vaccine 2008 Conference
11. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Reston, VA (PRWEB) January 15, 2014 ... education have continued their sponsorship of an annual competition ... interest in, and access to, innovative STEM study. The ... , TEAMS: Tests of Engineering Aptitude, Mathematics, and ...
(Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... CALGARY , June 1 /PRNewswire-FirstCall/ - Oncolytics ... that it has received approval from the Belgian Federal ... its Phase 3 trial examining REOLYSIN in combination with ... neck cancers. This is the same trial that was ...
... development that could lead to novel carbon composites and ... Institute of Technology today unveiled a new method for ... graphene. The research is available online in the ... graphene sheets make graphite, which has been commonly used ...
... SHENZHEN, China , May 28 /PRNewswire-Asia-FirstCall/ -- Huiheng Medical,Inc. (OTC ... China , will host a conference call,discussing its financial results for the period ended ... , , , ... , , ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4Liquid method: pure graphene production 2Huiheng Medical, Inc. Announces Conference Call to Discuss First Quarter 2010 Results 2
(Date:4/17/2014)... Professor Luca Razzari of the nergie Matriaux Tlcommunications ... from the John R. Evans Leaders Fund of ... acquisition of state-of-the-art biotech and nanophotonics equipment. To ... the Ministre de l,Enseignement suprieur, de la Recherche, ... These new laboratories will help us develop new ...
(Date:4/17/2014)... University engineer has developed a patented technique that ... devices. The same technique could help police during ... and Kay L. Theede chair in engineering and ... his research team have created a template-based system ... trunks. The distance detection method called stand-off ...
(Date:4/17/2014)... If a restaurant ... he can expect his premises to be trashed. Warnings like ... is enough to make restaurant owners pay up. Similarly, mafia-like ... in other birds, nests. If the host birds throw the ... destroying the entire nest. Consequently, it is beneficial for hosts ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2Patented research remotely detects nitrogen-rich explosives 2Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... Ebola virus, an emerging public health concern in Africa ... feared of exotic pathogens. Due to its virulent ... scientists studying the agent have had to work under ... few highly specialized labs and hampering the ability of ...
... FOR IMMEDIATE RELEASE From and for ... and Food Chemistry Wishing your Valentine good heart ... consider the food some people love to hate, and hand ... box of chocolates. Researchers in Connecticut are reporting impressive new ...
... A study by the University of Exeter has ... wild for conservation projects. Published online in the ... survival rates of captive carnivores that are released ... in three captive-born carnivores survives in the wild, ...
Cached Biology News:Ebola virus disarmed by excising a single gene 2Ebola virus disarmed by excising a single gene 3American Chemical Society's Weekly PressPac -- Jan. 16, 2008 2American Chemical Society's Weekly PressPac -- Jan. 16, 2008 3American Chemical Society's Weekly PressPac -- Jan. 16, 2008 4American Chemical Society's Weekly PressPac -- Jan. 16, 2008 5American Chemical Society's Weekly PressPac -- Jan. 16, 2008 6American Chemical Society's Weekly PressPac -- Jan. 16, 2008 7American Chemical Society's Weekly PressPac -- Jan. 16, 2008 8American Chemical Society's Weekly PressPac -- Jan. 16, 2008 9Captive carnivores not up to wild living 2
... trinor Prostaglandin F2α isopropyl ester (15(R)-17-phenyl ... latanoprost-related isomer containing both a double ... (β) hydroxyl group at C-15. Similar ... ester is a potential impurity in ...
... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. Feature: tissue-culture treated yes ... cm 2 D H 60 ...
... bind specifically to Fc regions of many ... conjugates are commonly used as affinity adsorbents ... from serum, hybridoma ascites fluids, tissue culture ... are also commonly used to capture immune ...
... min) assay can detect H2O2 or peroxidase ... H2O2 oxidizes ADHP in a 1:1 stoichiometry ... at 530-571 nm, emission at 590-600 nm). ... a one-step, homogeneous, no wash assay system. ...
Biology Products: